Evaluation of the effect of SINA anti-flu natural product on COVID-19

interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization method will be blocked randomization (Blocks of size 4). Randomization units are individuals. Eighty outpatients referred to the hospital emergency department are randomly assigned to one of the two intervention and control groups according to form of random string produced by online random allocation , Blinding description: Study participants, the clinical observer, the data collector, and the data analyzer are kept blind to the study groups. Blinding will be done using a placebo in the control group. 2-3 Inclusion criteria: Male or female patients 18 years old and older with COVID-19 positive coronavirus 19 PCR Ground glass view at low-dose CT scan Arterial oxygen saturation less than 93% Consciously completed consent form completed by the patient or the patient's supervisor Exclusion criteria: History of pulmonary malignancy History of asthma or COPD History of Disabling disease or malignancy Liver or kidney disorders COVID-19. U07.2 COVID-19, virus not identified, COVID-19;U07.2 Intervention 1: Intervention group: The product includes herbal syrup (Echinacea, thyme, hyssop, Chebulic Myrobaan), honey and glycyrrhizin drop.Dosage of syrup: every 6 hours;10 cc. Dosage of drop: 20 drops after lunch and dinner. In the intervention group, conventional medicine is used according to the latest protocol of the Ministry of Health at the begining of the study (Azithromycin 250mg once a day and naproxen 250mg twice a day). Intervention 2: Control group: In this group, the common drug is used according to the latest protocol of the Ministry of Health at the begining of the study that is similar to the common drug medicine in the herbal product group. Measurement of cough severity. Timepoint: Day 1 before and at the end of treatment. Method of measurement: Standard cough questionnaire.;Severity of shortness of breath. Timepoint: Day 1 before and at the end of treatment. Method of measurement: Shortness Of Breath With Daily Activity (SOBDA) Questionnaire.;Lung radiologic changes. Timepoint: At beginning and end of the study. Method of measurement: Chest CT scan.